News

CARB-X to invest up to $4.1M into Summit Therapeutics antibiotic for CRE-caused multidrug-resistant infections

Up to $4.1 million in non-dilutive funding from nonprofit CARB-X was announced this week for Summit Therapeutics to help develop a first-in-class antibiotic to treat multidrug-resistant infections, and specifically, carbapenem-resistant Enterobacteriaceae (CRE) infections.

This funding will aid Summit in progressing its SMT-738 antibiotic project through both preclinical and Phase 1a clinical development. Discovered by Summit’s proprietary Discuva Platform, the antibiotic acts through an essential lipid transport system in Gram-negative bacteria. Pairing with this target, the antibiotic could help reduce the risk of pre-existing resistance and allow for more effective treatment of CRE-related infections that currently have little treatment recourse.

Phase one studies are expected to begin in 2023. What’s more, the company could receive an additional $3.7 million in funding for its efforts if CARB-X deems certain milestones to be achieved.

“The world urgently needs innovative therapeutics to address life-threatening pathogens that are constantly developing new ways of resisting the effects of antibiotics that are designed to kill them,” Erin Duffy, R&D Chief of CARB-X, said. “Summit’s SMT-738 represents a novel class that has a new mechanism of inhibition of bacterial cell membrane biosynthesis. These degrees of novelty combine to offer a potential advantage where antibiotic resistance is concerned.”

Drug-resistant pathogens have been dubbed a critical priority by the World Health Organization (WHO) and an urgent threat by the U.S. Centers for Disease Control and Prevention (CDC). CRE, in particular, are a family of bacteria that cause deadly infections that spread quickly and have little means of treatment. They resist all existing antibiotics and are particularly prevalent in healthcare settings. Responsible for an estimated 1,100 patient deaths each year, according to the CDC, they can also cause bloodstream infections, urinary tract infections, and hospital-acquired pneumonia.

“With the growing threat of antibiotic resistance, particularly with respect to CRE infections, SMT-738 is clearly differentiated from all agents, including the beta-lactamase inhibitors, that are currently used to treat such infections,” Dr. David Powell, Summit’s Chief Scientific Officer, said. “Having encountered no existing resistance in clinical isolates to the novel chemistry of SMT-738, the ability of our drug molecule to reset the clock against growing resistance is critical in our collective fight against these pathogens causing an urgent public health threat.”

Chris Galford

Recent Posts

Sen. Barrasso raises concerns over DOE’s ability to protect AI R&D from China

With artificial intelligence (AI) the increasing focus of interest for Washington and private companies, U.S.…

1 day ago

Senate advances legislation that emphasizes federal building security

The Senate greenlit the Federal Building Security Act (S. 3613) this week, moving to the…

1 day ago

Senate bill seeks to compel national security risk analysis of economic integration with China

A bipartisan group of senators recently introduced the American Economic Independence Act, which would require…

2 days ago

Sen. Peters presses federal agencies to increase cybersecurity for American health care

Citing cases where cyberattacks targeted health care systems in the United States, U.S. Sen. Gary…

2 days ago

U.S. Justice Department launches National Extreme Risk Protection Order Resource Center to curb gun violence

The U.S. Department of Justice recently launched a new resource center – the National Extreme…

3 days ago

Government funding agreement includes $3M allotment to create Northern Border security center

Among the provisions included in the recent $1.2 trillion funding agreement signed by President Joe…

3 days ago

This website uses cookies.